Drug Trial Radar · NCT04760769
Open-label Trial in Parkinson's Disease (PD)
Last checked: Nov 19, 2026Latest source record: Dec 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
992
Actual
Start
Feb 24, 2021
Primary completion
Dec 1, 2025
Study completion Dec 1, 2025
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Feb 18, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of long-term administration of flexible doses of tavapadon in participants with Parkinson's Disease.
Conditions
- Parkinson Disease
Interventions
TavapadonDrug
Participants will receive Tavapadon at a dose of (5 to 15) mg QD, orally during a 58-week treatment period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: 62 Weeks
- Number of Participants Who Discontinued Study TreatmentTime frame: 62 Weeks
- Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease Rating Scale (QUIP-RS)Time frame: 58 Weeks
- Epworth Sleepiness Scale (ESS)Time frame: 58 Weeks
- Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: 60 Weeks
- Study Medication Withdrawal Questionnaire (SMWQ)Time frame: 60 Weeks
- Change From Baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I, II and IIITime frame: 60 Weeks
- Change From Baseline in the Hauser diaryTime frame: 58 Weeks
- Change From Baseline in the EuroQol 5 Dimension 5 Level (EQ-5D-5L) IndexTime frame: Baseline (Day 1), Weeks 32 and 58
- Change From Baseline in the EuroQol 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scores (VAS)Time frame: Baseline (Day 1), Weeks 32 and 58
Locations
140 sites in 14 countries. Site status is shown where the registry gives one.
Birmingham, Alabama
Birmingham, Alabama
Pheonix, Arizona
Phoenix, Arizona
Little Rock, Arkansas
Little Rock, Arkansas
Fountain Valley, California
Fountain Valley, California
Fresno, California
Fresno, California
Los Angeles, California
Los Angeles, California
Pasadena, California
Pasadena, California
Reseda, California
Reseda, California
Englewood, Colorado
Englewood, Colorado
Florida, United States
Adventura, Florida
Boca Raton, Florida
Boca Raton, Florida
Coral Springs, Florida
Coral Springs, Florida
Maitland, Florida
Maitland, Florida
Naples, Florida
Naples, Florida
Ocala, Florida
Ocala, Florida
Port Charlotte, Florida
Port Charlotte, Florida
Port Orange, Florida
Port Orange, Florida
Tampa, Florida
Tampa, Florida
Winter Park, Florida
Winter Park, Florida
Augusta, Georgia
Augusta, Georgia
Chicago, Illinois
Chicago, Illinois
Winfield, Illinois
Winfield, Illinois
Kansas City
Kansas City, Kansas
Lexington, Kentucky
Lexington, Kentucky
Scarborough, Maine
Scarborough, Maine
Boston, Massachusettes
Boston, Massachusetts
Lawrence, Massachusetts
Lawrence, Massachusetts
East Lansing, Michigan
East Lansing, Michigan
West Bloomfield
West Bloomfield, Michigan
Las Vegas, Nevada
Las Vegas, Nevada
Camden, New Jersey
Camden, New Jersey
Albany, New York
Albany, New York
Syracuse, New York
Syracuse, New York
Asheville, North Carolina
Asheville, North Carolina
Durham, North Carolina
Durham, North Carolina
Cincinnati, Ohio
Cincinnati, Ohio
Cleveland, Ohio
Cleveland, Ohio
Columbus, Ohio
Columbus, Ohio
Dayton, Ohio
Dayton, Ohio
Toledo, Ohio
Toledo, Ohio
Showing 40 of 140 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.